Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males or females 18 to 65 years of age at the time of screening
Baseline percent of predicted FEV1 ≥ 50% to ≤ 80% at screening
At least 12% reversibility over baseline FEV1 with beta agonist inhalation, which can be demonstrated in the office or documented by medical record within the past 12 months
Inhaled corticosteroid (ICS) ≥ 200 and ≤ 1000 µg/day fluticasone or equivalent. Stable ICS dose for ≥ 30 days before screening and dose expected to remain stable during treatment with investigational agent. Must have used ICS for at least the last 3 consecutive months before screening
If receiving allergen immunotherapy, a stable dose for \> 3 months before screening and anticipated to remain stable for the duration of the study
Positive to skin prick or RAST
Ongoing asthma symptoms with ACQ score at screening and baseline ≥ 1.5 points
Nonsmoker or ex-smoker with \< 10 pack-years (eg, 1 pack per day for 10 years) who stopped ≥ 1 year ago
You may not be if
Acute asthma exacerbation requiring emergency room (ER) treatment or hospitalization within 3 months
History of endotracheal intubation for asthma-related exacerbation within 3 years of screening
Respiratory illness within 4 weeks of screening
History of chronic obstructive pulmonary disease (COPD) or other chronic pulmonary condition other than asthma
Received long-acting beta agonist, theophylline, inhaled anticholinergics, oral beta 2 agonists, or cromolyn therapeutics within 1 week of first run-in visit.
Leukotriene antagonists within 2 weeks before first run-in visit
Oral or parenteral corticosteroids within 6 weeks before first run-in visit
Live/attenuated vaccinations within 4 weeks of screening or during the study
